Allakos Inc. (ALLK)
| Market Cap | 342.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -403.22M |
| Shares Out | 54.84M |
| EPS (ttm) | -7.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 953,349 |
| Open | 6.19 |
| Previous Close | 6.12 |
| Day's Range | 5.74 - 6.28 |
| 52-Week Range | 2.54 - 112.87 |
| Beta | 0.65 |
| Analysts | Hold |
| Price Target | 6.69 (+7.0%) |
| Earnings Date | Nov 7, 2022 |
About ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (A... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is 6.69, which is an increase of 7.04% from the latest price.
News
3 Healthcare Stocks to Sell Before They Die
The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.
Why Is Allakos (ALLK) Stock Soaring 25% Today?
On Monday, biotechnology firm Allakos (NASDAQ: ALLK ) announced a public offering that raised gross proceeds of approximately $150 million, sending ALLK stock soaring 25% in the morning session before p...
Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria...
Top-line Phase 2b results expected in the second half of 2023 Top-line Phase 2b results expected in the second half of 2023
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint –
Why Allakos Stock Is on Fire Today
Investors appear to be getting into position ahead of a major upcoming catalyst.
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inf...
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inf...
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Manage...
Los Angeles, California--(Newsfile Corp. - June 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by t...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Managemen...
Los Angeles, California--(Newsfile Corp. - June 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by th...
INVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Al...
Los Angeles, California--(Newsfile Corp. - June 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by th...
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and in...
Why Allakos Stock Sank 17.3% in February
The biotech stock has lost roughly 96% of its value over the last year.
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and ...
Allakos Inc. (ALLK) Flat As Market Gains: What You Should Know
Allakos Inc. (ALLK) closed at $6.54 in the latest trading session, marking no change from the prior day.
Allakos Inc. (ALLK) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Allakos Inc. (ALLK) closed at $6.81, marking a -0.58% move from the previous day.
5 Important Investing Lessons From Allakos' Price Collapse
ALLK stock is a gamble now even after falling about 85% off its 52-week high. Allakos' slide offers investors with a learning opportunity.
Allakos Is a Cautionary Tale of Biopharmaceutical Investing
ALLK stock dropped off a cliff following disappointing study results, which illustrates what can go wrong in risky biopharma equities. The post Allakos Is a Cautionary Tale of Biopharmaceutical Investin...
Why Allakos Stock Plummeted 87.5% in the Last Month of 2021
The biotech stock is now down roughly 93% over the last year.
After a Clinical-Data Bombshell, Allakos Might Actually Be a Buy
After a well-publicized clinical-data letdown, it may be time to go long as the worst-case scenario has already been priced into ALLK stock. The post After a Clinical-Data Bombshell, Allakos Might Actua...
Down 86.1% in 4 Weeks, Here's Why Allakos Inc. (ALLK) Looks Ripe for a Turnaround
Allakos Inc. (ALLK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimate...
Allakos Inc. down 80% after announcing topline phase III results from its Enigma II clinical study
Allakos Inc (NASDAQ: ALLK) announced its results from Enigma II, Phase III placebo-controlled, double-blind clinical research of lirentelimab on people battling EG (eosinophilic gastritis) and went up b...
Why Allakos Shares Are Plummeting Today
Allakos Inc (NASDAQ: ALLK) is trading significantly lower Wednesday after the company announced ENIGMA 2 and KRYPTOS studies did not achieve statistical significance on the patient reported symptomatic ...
ALLK Stock Alert: Why Is Allakos Absolutely Plunging Today?
Allakos' recent study results have sent ALLK stock straight to the bottom. Here's what investors should know right now.
Why Allakos Stock Is Crashing Today
The company announced disappointing results from two clinical studies.